Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 18Lymphoma, Large B-Cell, Diffuse 16Leukemia, Myeloid, Acute 16Hodgkin Disease 16Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lung Neoplasms 12Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Lymphoma, B-Cell 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 6Recurrence 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Congenital Abnormalities 4Waldenstrom Macroglobulinemia 3Plasmablastic Lymphoma 3Ovarian Neoplasms 3Lymphoma, Primary Effusion 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

Cisplatin 4Etoposide 2veliparib 1sagopilone 1sacituzumab govitecan 1pomalidomide 1pembrolizumab 1etoposide phosphate 1Topotecan 1Tomography, X-Ray Computed 1Temozolomide 1Rhenium 1Radiation 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Penfluridol 1Pemetrexed 1PT-100 dipeptide 1Histamine Antagonists 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Small Cell × Etoposide × Clear all
NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡